• Explore /
  • Poster
  • / Immune activation in first-in-human anti-macrophage antibody (anti-Clever-1 mAb; FP-1305) phase I/II MATINS trial: Part I dose-escalation, safety, and efficacy results.

Immune activation in first-in-human anti-macrophage antibody (anti-Clever-1 mAb; FP-1305) phase I/II MATINS trial: Part I dose-escalation, safety, and efficacy results.

Abstract Poster

Authors

null

Petri Bono

Terveystalo Finland and University of Helsinki, Helsinki, Finland

Petri Bono , Reetta Virtakoivu , Felix Vaura , Panu Jaakkola , Shishir Shetty , Alain Thibault , Maja J.A. de Jonge , Anna Rachel Minchom , Yuk Ting Ma , Christina Yap , Debbie Robbrecht , Annika Pasanen , Tanja Skytta , Romillie Cruz , Markku Jalkanen , Sirpa Jalkanen , Jami Mandelin , Matti Karvonen , Jussi Koivunen , Maija Hollmen

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Poster Session

Session Title

Developmental Therapeutics—Immunotherapy

Track

Developmental Therapeutics—Immunotherapy

Sub Track

New Targets and New Technologies (IO)

Clinical Trial Registration Number

2018-002732-24

Citation

J Clin Oncol 38: 2020 (suppl; abstr 3097)

DOI

10.1200/JCO.2020.38.15_suppl.3097

Abstract #

3097

Poster Bd #

161

Abstract Disclosures

Similar Posters

First Author: Igor Tsaur

First Author: Margaret K. Callahan

First Author: Thorsten Oliver Goetze

First Author: Shubham Pant